YOKOHAMA, Japan–(BUSINESS WIRE)–CoreTissue BioEngineering Inc., a medical machine firm growing a man-made ligament derived from decellularized animal tissue, was accepted into Johnson & Johnson Innovation – JPOD @ Boston.
CoreTissue BioEngineering will develop its footprint and speed up enterprise improvement within the US by its assist crew and choose key opinion leaders (KOLs).
About CoreTissue BioEngineering Inc.
Based mostly in Yokohama, Japan, CoreTissue BioEngineering, Inc. is a spinout firm from Waseda College in Japan. We really feel our crew of Harvard-trained biomedical scientist, seasoned senior administration in medical machine improvement, and skilled medical analysis skilled has the fitting skills to hold this mission to potential success.
Following our success in growing synthetic ligament for ACL reconstruction surgical procedure, we plan to additional apply our know-how platform to the event of medical units for the broader human musculoskeletal system.
CoreTissue BioEngineering has already validated a proof-of-concept of the product in an ovine massive animal examine with a prototype developed utilizing these applied sciences. The corporate has obtained sturdy backing from the Japanese authorities, the Japan Company for Medical Analysis and Improvement (AMED) for improvement from early feasibility by pivotal trial.
For extra data, go to https://www.coretissue.com/?lang=en
The content material is by Enterprise Wire. Headlines of At this time Media will not be liable for the content material offered or any hyperlinks associated to this content material. Headlines of At this time Media will not be liable for the correctness, topicality or the standard of the content material.